Evidence map›Paper›PMID 41505334›Full record

SynthesisThe Journal of clinical endocrinology and metabolism2026

Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials.

Agathoklis Efthymiadis, Konstantinos Tsikopoulos, Edouard G Mills, Andrew Milne, Waljit S Dhillo, Ali Abbara, Alexander N Comninos

Abstract readSystematic ReviewNetwork Meta-Analysis
In one paragraph

Synthesis in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Agathoklis EfthymiadisSection of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.
Konstantinos TsikopoulosThe Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
Edouard G MillsSection of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.
Andrew MilneHammersmith Campus Library, Imperial College London, London W12 0NN, UK.
Waljit S DhilloSection of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.ORCID 0000-0001-5950-4316
Ali AbbaraSection of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.ORCID 0000-0003-2795-5256
Alexander N ComninosSection of Endocrinology and Investigative Medicine, Imperial College London, London W12 0NN, UK.ORCID 0000-0002-7104-2297

Funding

MRCNHSNIHR CS-2018-18-ST2-002
6 · The paper itself

Abstract

contextWomen with functional hypothalamic amenorrhea (FHA) are at high risk of poor bone health. When lifestyle measures fail to restore menses, pharmacological interventions are needed for bone health, but comparative efficacy remains unclear.

objectiveTo compare the efficacy of available pharmacological interventions to improve bone mineral density (BMD), in women with FHA, employing network meta-analysis (NMA). DATA SOURCES: Medline, Embase, Emcare, Cochrane CENTRAL, ISRCTN, and ClinicalTrials.gov were searched up to 20 September 2025. STUDY SELECTION: Eligible randomized-controlled trials evaluated pharmacological interventions for lumbar spine (LS), femoral neck (FN), or total hip (TH) BMD in women with FHA. Two independent reviewers screened titles, abstracts, and texts. DATA EXTRACTION: Two reviewers independently extracted data following the Preferred Reporting Items for Systematic Reviews-network meta-analysis guidelines. Outcomes were expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs) using random-effects NMA. Evidence certainty was assessed with CINeMA. DATA SYNTHESIS &

resultsThirteen randomized-controlled trials (n = 897 participant observations across all pharmacotherapy comparisons) were included (LS BMD: n = 897; FN BMD: n = 370; TH BMD: n = 750). Transdermal hormone replacement therapy (HRT) was superior to control (placebo or no intervention) for LS BMD with SMD: 0.34 (0.03, 0.64) and FN BMD with SMD: 0.57 (0.04, 1.10). Oral HRT and the combined oral contraceptive pill (COCP) showed no significant benefit for any BMD site. Teriparatide was superior to transdermal HRT and COCP for LS BMD with SMDs: 1.48 (0.38, 2.59) and 1.75 (0.66, 2.83), but not FN or TH BMD.

conclusionsTransdermal HRT and teriparatide improve LS BMD in women with FHA, with transdermal HRT also improving FN BMD. STUDY REGISTRATION: PROSPERO (CRD42024576872).

Indexed as

AmenorrheaBone DensityBone Density Conservation AgentsHypothalamic DiseasesFemaleHumansRandomized Controlled Trials as TopicBone Density Conservation Agentsanorexia nervosacombined oral contraceptive pillhormone replacement therapyhypothalamic amenorrheaosteoporosis

Identifiers

PMID41505334
PMCPMC13099214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.